Last reviewed · How we verify
NCT05639738
Assessment of Clinical, Biological and Biometrological Paramaters in Adult Subjects Suffering From AD
NA trial testing Clinical and instrumental measurements in Dermatitis, Atopic in 12 participants. Terminated before completion.
15 June 2022
Quick facts
| Lead sponsor | Pierre Fabre Dermo Cosmetique |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 12 |
| Start date | 8 March 2022 |
| Primary completion | 15 June 2022 |
| Estimated completion | 15 June 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- Clinical and instrumental measurements
Conditions studied
- Dermatitis, Atopic — all drugs for Dermatitis, Atopic →
Sponsor
Pierre Fabre Dermo Cosmetique — full company profile →
Who can join
Adults 18 to 50, any sex, with Dermatitis, Atopic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to collect different parameters (clinical, biological and biometrological) of Atopic Dermatitis (AD) in order to identify which factors are modified during the flare-up phase.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05639738
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dermatitis, Atopic
Currently open trials in the same condition.
- NCT07230860 — A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis · Phase 2 · recruiting
- NCT06899204 — Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate · recruiting
- NCT07042126 — Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis · Phase 3 · recruiting
- NCT06881251 — A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) · Phase 2 · active not recruiting
- NCT06554847 — Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis · Phase 3 · active not recruiting
Other Pierre Fabre Dermo Cosmetique trials
Trials by the same sponsor.
- NCT07014007 — Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Weeks · NA · not yet recruiting
- NCT07166484 — Assessment of the Effect of the Product RV2666C Formula LA2984 Compared to an Untreated Area With an Epidermally Ablated · not yet recruiting
- NCT06983561 — Description of the Population With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments and Needs Regard · recruiting
- NCT07341659 — Efficacy of Cosmetic Product RV3278B-OS0386 in the Maintenance Phase After Oral Isotretinoin Treatment of Adults Subject · NA · active not recruiting
- NCT06800755 — Evaluation of the Efficacy and Tolerance of the Medical Device RL3020-DP0364 in Adult Population With Stable Mild Plaque · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05639738 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pierre Fabre Dermo Cosmetique
- Last refreshed: 6 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05639738.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing